본문 바로가기
KERD
논문KCI 등재

Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects

김계환|윤상진|김태범
대한배뇨장애요실금학회 (Korean Continence Society)|2010.04|International Neurourology Journal|제14권 제1호|pp. 7-12

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Tadalafil; Erectile dysfunction; Benign

초록

Purpose: Benign prostatic hyperplasia is often accompanied by age-related comorbidity, such as erectile dysfunction (ED). Recent data suggest an association between ED and lower urinary tract symptoms (LUTS), and increasing evidence indicates that the clinical use of phosphodiesterase type 5 (PDE5) inhibitors provides relief from LUTS. The aim of the present study was to investigate the effects of tadalafil (20 mg once every 3 days for 12 weeks, p.o.) in men with moderate-to-severe ED and LUTS and to investigate the duration of the effects of tadalafil beyond treatment cessation. Metrials and Methods: Men with an International Index of Erectile Function-5 (IIEF-5) score of less than 11 (representing "moderate-to- severe" ED status) and with an International Prostate Symptom Score (IPSS) of more than 8 (representing "moderate-to-severe" LUTS status) were enrolled. IPSS (total score, storage subscore, and voiding subscore) and IIEF-5 scores before treatment (baseline), during treatment (weeks 4 and 12 after treatment commencement), and after treatment (weeks 16 and 20after treatment commencement) were compared. Results: IPSS and IIEF-5 scores were significantly different between baseline and week 12 after treatment commencement. Furthermore, these scores were significantly different between baseline and week 20 after treatment commencement. However, except for IIEF-5 scores, no significant differences were observed between week 12 and week 20. Conclusions: Treatment with 20 mg tadalafil (once every 3 days) had beneficial effects on LUTS and ED beyond treatment cessation in patients with moderate-to-severe ED and LUTS.

Abstract

Purpose: Benign prostatic hyperplasia is often accompanied by age-related comorbidity, such as erectile dysfunction (ED). Recent data suggest an association between ED and lower urinary tract symptoms (LUTS), and increasing evidence indicates that the clinical use of phosphodiesterase type 5 (PDE5) inhibitors provides relief from LUTS. The aim of the present study was to investigate the effects of tadalafil (20 mg once every 3 days for 12 weeks, p.o.) in men with moderate-to-severe ED and LUTS and to investigate the duration of the effects of tadalafil beyond treatment cessation. Metrials and Methods: Men with an International Index of Erectile Function-5 (IIEF-5) score of less than 11 (representing "moderate-to- severe" ED status) and with an International Prostate Symptom Score (IPSS) of more than 8 (representing "moderate-to-severe" LUTS status) were enrolled. IPSS (total score, storage subscore, and voiding subscore) and IIEF-5 scores before treatment (baseline), during treatment (weeks 4 and 12 after treatment commencement), and after treatment (weeks 16 and 20after treatment commencement) were compared. Results: IPSS and IIEF-5 scores were significantly different between baseline and week 12 after treatment commencement. Furthermore, these scores were significantly different between baseline and week 20 after treatment commencement. However, except for IIEF-5 scores, no significant differences were observed between week 12 and week 20. Conclusions: Treatment with 20 mg tadalafil (once every 3 days) had beneficial effects on LUTS and ED beyond treatment cessation in patients with moderate-to-severe ED and LUTS.

참고문헌 (25)

  1. Calais DS, "Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study", Eur Urol, 31, pp.272~280 (1997)
  2. Kirby RS, "The natural history of benign prostatic hyperplasia: what have we learned in the last decade?", Urology, 56, pp.3~6 (2000)
  3. Madersbacher S, "The long-term outcome of medical therapy for BPH", Eur Urol, 51, pp.1522~1533 (2007)
  4. Kasturi S, "Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia", Curr Urol Rep, 7, pp.288~292 (2006)
  5. Costabile RA, "How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia?", J Sex Med, 3, pp.678~681 (2006)
  6. Uckert S, "Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate", J Urol, 166, pp.2484~2490 (2001)
  7. Uckert S, "Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate", Eur Urol, 49, pp.740~745 (2006)
  8. Schwarz ER, "The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems", Int J Impot Res, 19, pp.139~148 (2007)
  9. Ziegler D, "Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction", JSex Med, 3, pp.883~891 (2006)
  10. Rubio-Aurioles E, "Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossoverstudy", J Sex Med, 3, pp.1037~1049 (2006)
  11. Padma-Nathan H, "PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy", Rev Urol, 7(Suppl 2), pp.33~38 (2005)
  12. Aversa A, "Phosphodie- sterase 5 inhibitors in the treatment of rectile dys- function", Curr Pharm Des, 12, pp.3467~3468 (2006)
  13. Christiansen E, "Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal", Int J Impot Res, 12, pp.177~182 (2000)
  14. McMahon CG, "Treatment of erectile dysfunction with chronic dosing of tadalafil", Eur Urol, 50, pp.215~217 (2006)
  15. Sommer F, "Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial", Asian J Androl, 9, pp.134~141 (2007)
  16. Rosano GM, "Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk", Eur Urol, 47, pp.214~220 (2005)
  17. Sommer F, "Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhi- bitors", World J Urol, 23, pp.385~392 (2005)
  18. Porst H, "Elion-Mboussa A et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial", Eur Urol, 50, pp.351~359 (2006)
  19. Reginster JY, "Adherence,patient preference and dosing frequency: understanding the relationship", Bone, 38, pp.2~6 (2006)
  20. Burkhart PV, "Adherence to long-term therapies: evidence for action", J Nurs Scholarsh, 35, pp.207~ (2003)
  21. Mirone V, "An evaluation of an alternative dosing regimen with tadalafil, 3 times", week, for men with erectile dysfunction: SURE study in 14 European countries, 2005, pp.47, 846~854
  22. Tinel H, "Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms", BJU Int, 98, pp.1259~1263 (2006)
  23. Filippi S, "Characterization and functional role of androgen-dependent PDE5 activity in the bladder", Endocrinology, 148, pp.1019~1029 (2007)
  24. McVary KT, "Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial", J Urol, 177, pp.1071~1077 (2007)
  25. McVary KT, "Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia", J Urol, 177, pp.1401~1407 (2007)

관련 논문AI추천

A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α-Blockers and α-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction천준, 최훈, 김재헌, 김현정, 문두건, 배재현, 여정균대한배뇨장애요실금학회 · International Neurourology Journal2015 · 제19권 제4호Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study윤병일, 이승환, 정문수연세대학교의과대학 · Yonsei Medical Journal2017 · 제58권 제4호Clinical Course of the Benign Prostate Hyplasia Patients during the Intermittent Use of 5-Alpha Reductase InhibitorsByounghoon Kim, In-Chang Cho, Kwi Bok Choi, Seung Ki Min대한요로생식기감염학회 · Urogenital Tract Infection2019 · 제14권 제3호A Prospective, Multicenter, Open-Label Study of Dose Escalation Therapy in Male Patients With Nocturia Refractory to 0.2-mg Tamsulosin MonotherapyHo Song Yu, Jeong Woo Lee, Jihyeong Yu, Min Chul Cho, Sung Yong Cho대한배뇨장애요실금학회 · International Neurourology Journal2019 · 제23권 제4호Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia강세희, 고준성, 김준철, 김효신, 조강준대한배뇨장애요실금학회 · International Neurourology Journal2011 · 제15권 제3호Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review강태욱, 김명하, 김수진, 정재흥대한배뇨장애요실금학회 · International Neurourology Journal2021 · 제25권 제3호

이 간행물의 다른 논문 (10건)

Experimental Animal Models of Neurogenic Bladder Dysfunction유구한, 이선주pp. 1-6Influence of Obesity on Short-term Surgical Outcome of the Transobturator Tape Procedure in Patients with Stress Urinary Incontinence최동언, 김원재, 김용준, 윤석중, 이상철, 김원태pp. 13-19Effects of Transobturator Adjustable Tape Sling Procedure on the Therapeutic Outcome in Patients with Stress Urinary Incontinence and Detrusor Underactivity조대기, 양승애, 서주태pp. 20-25Predictors of Postoperative Voiding Dysfunction following Transobsturator Sling Procedures in Patients with Stress Urinary Incontinence이영구, 조성태, 김기경, 송형철, 송하정pp. 26-33Efficacy and Safety of Tension-free Placement of Gynemesh PS for the Treatment of Anterior Vaginal Wall Prola김태헌, 주명수, 서주태, 이영숙, 한덕현, 이정주, 정병수, 임수현, 이정구, 이규성pp. 34-42
원문 보기